GUFICBIO vs NGLFINE: Stock Comparison

Gufic Biosciences Limited vs NGL Fine-Chem Limited

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Gufic Biosciences Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Gufic Biosciences Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GUFICBIO is more favourable on 2 of 13 scored metrics and NGLFINE on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GUFICBIO is the larger company
₹3,846 Cr vs ₹2,015 Cr
P/E Ratio
NGLFINE has a lower P/E
41.23x vs 62.05x
P/B Ratio
GUFICBIO has a lower P/B
5.99x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹6.42
Dividend Yield
NGLFINE has a higher dividend yield
0.05% vs 0.03%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 22.8%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs 183.1%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs 22.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGUFICBIONGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGUFICBIONGLFINE
Live Price₹386.7₹3,260
Day Change-2.52%0.7%
Volume43,8985,953
52-Week High₹448₹3,329
52-Week Low₹268₹1,175.5
Distance from 52W High-13.68%-2.07%

Valuation

MetricGUFICBIONGLFINE
Market Cap₹3,846 Cr₹2,015 Cr
P/E Ratio62.05x41.23x
P/B Ratio5.99x6.03x
EPS₹6.42₹78.04
Book Value₹66.2₹532.95
Dividend Yield0.03%0.05%

Growth

MetricGUFICBIONGLFINE
Revenue Growth (TTM YoY)22.8%57.2%
EPS Growth (TTM YoY)183.1%1,539.8%
Qtr Sales Growth22.8%57.1%
Qtr Profit Growth184%2,398%

Profitability & Leverage

MetricGUFICBIONGLFINE
ROE10.1%15.7%
ROCE12.3%17%
Net Margin6.8%9.59%
Operating Margin16%14.5%
Debt to Equity0.61x0.33x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricGUFICBIONGLFINE
Promoter Holding72.5%72.74%
FII Holding0.42% 0.02 pp0.03% 0.03 pp
DII Holding3.83% 0.09 pp0%
Public Holding23.24% 0.08 pp27.24% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Gufic Biosciences Limited and NGL Fine-Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.